Business Operation · 2025
In this section22 topics
- Corporate Information4 items
- Dividend Policy2 items
- Major Shareholders1 item
- Business Strategies Overview7 items
- Material Changes & Developments2 items
- Use of Proceeds from Securities Offerings2 items
- Commitments Made in the Registration Statement2 items
- Group Operating-Structure Policy1 item
- Companies Where the Company Holds ≥10%1 item
- Shareholders with Potential Conflict of Interest1 item
- Relationships Among Major Shareholders1 item
- Shareholders' Agreement1 item
- Shareholding Diagram (Group Structure)3 items
- Income Structure3 items
- Product / Service Characteristics3 items
- Research & Development2 items
- Assets Used in the Business6 items
- Marketing Policy & Competition4 items
- Procurement of Products & Services2 items
- Projects Under Construction1 item
- Debentures & Bills of Exchange1 item
- Convertible Securities3 items
Corporate Information
Company Name
VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED
Telephone
0-2561-1111, 0-2561-1258-67
Website
http://www.vibhavadi.com
cs@vibhavadi.com
Dividend Policy
Dividend Policy
The Company has a policy to pay dividends at a rate of not less than 50% of its net profit after corporate income tax and all types of reserves as stipulated by law and the Company. However, such dividend payments will take into consideration the following factors: the Company's operating results, financial position, liquidity, investment plans of the Company and its subsidiaries, and other factors related to the Company's management and future business expansion. The aforementioned dividend payments must be approved by the Board of Directors and the shareholders' meeting, with the exception of interim dividend payments which are approved by a resolution of the Board of Directors' meeting.
Historical Dividend Payments
| This Year | Last Year | 2 Years Ago | 3 Years Ago | 4 Years Ago | Metric | Description |
|---|---|---|---|---|---|---|
| 0.1 | 0.06 | 0.07 | 0.09 | 0.07 | Net profit per share (Baht : Share) | Net profit per share (baht : share) |
| 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | Dividend per share (Baht : Share) | Dividend per share (baht : share) |
| 0 | 0 | 0 | 0 | 0 | Dividend stock ratio (Number of original shares: dividend shares) | Ratio of stock dividend payment (existing share : stock dividend) |
| 0 | 0 | 0 | 0 | 0 | Dividend share value per share (Baht : Share) | Value of stock dividend per share (baht : share) |
| 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | Total dividend payment value (Baht : Share) | Total dividend payment (baht : share) |
| 60.89 | 83.03 | 72.99 | 64.18 | 75.3 | Dividend payout ratio to net profit (%) | Dividend payout ratio compared to net profit (%) |
Business Strategies Overview
Introduction
The Company aims to be a leading private hospital with outstanding characteristics within 5 years in terms of quality medical care, service, and personnel, under the framework of professional ethics that conducts its business with good governance, as well as caring about the environment and society. In this regard, the Board of Directors and the Company’s executives have jointly established the following vision, mission, values, and objectives:
Vision
“Committed to becoming a tertiary care provider driven by high quality health care and excellent service.”
Mission
To continuously develop to provide tertiary care through our Centers of Excellence.
To implement Smart Service / Smart Operation / Smart Hospital systems that support process optimization.
To gain customer trust through a service-oriented culture with happy employees
To continuously improve to bring the most value in the interest of our stakeholders, social environment, and governance.
Chairman's Message
Message from the Chairman of the Board of Directors
In the past year, the private hospital industry has continued to face several challenges, including economic volatility, rising medical costs, rapid technological changes, and increasing expectations of patients. Vibhavadi Hospital Public Company Limited (the “Company”) has continuously adapted its strategies to maintain competitiveness, while conducting its business with prudence under the principles of good corporate governance, alongside systematically enhancing the quality of medical treatment and services. The Company has demonstrated its commitment to continuous improvement and adaptability amid rapid changes in the economic, social, and technological landscape. As a result, in the past year, the Company was recognized as a constituent of the Thailand Sustainability Investment (SET ESG Ratings) with a rating of “A”, achieved an “Excellent” CGR score, and continued its membership in the Collective Action Against Corruption (CAC) Company’s strong commitment to sustainable and ethical business practices.
The Company places great importance on comprehensive risk management and is committed to driving the organization toward sustainable growth in line with international standards, with a focus on three key pillars:
Environmental (Environment): We strive to minimize environmental impact through efficient energy utilization, the initiation of greenhouse gas reduction projects, and responsible medical waste management.
Social (Social): We emphasize the quality of life of patients, medical personnel, and surrounding communities by enhancing service standards, promoting equitable access to healthcare, and ensuring workplace safety.
Governance (Governance): We conduct our business in accordance with good corporate governance principles—ensuring transparency, accountability, and consideration of all stakeholders—while fostering an organizational culture grounded in ethics and responsibility.
The Board of Directors and the management team remain committed to driving the Company toward sustainable and stable growth. For the year 2025, the Company reported total revenue of Baht 6,106.22 million, with hospital operation revenue of Baht 5,538.23 million, and net profit of Baht 1,813.16 million. As of December 31, 2025, the Company had total assets of Baht 21,678.27 million, total liabilities of Baht 9,202.10 million, and shareholders’ equity of Baht 12,476.17 million.
For 2026, Vibhavadi Hospital has established strategies to strengthen the organization for long-term growth, focusing on advancing medical excellence, adopting modern and high-efficiency technologies for treatment, and enhancing cost management efficiency. At the same time, the Company continues to emphasize sustainability and resilience in order to maintain competitiveness and deliver appropriate returns to shareholders.
On behalf of the Board of Directors, I would like to express our sincere appreciation to our customers, shareholders, business partners, and all stakeholders for their continued trust and support. I would also like to extend my gratitude to the management team, medical professionals, and all employees for their dedication and professionalism, as well as their service-minded commitment to patients. Together, we continue to create sustainable value for the business while upholding our responsibilities to society, communities, and the environment for enduring growth.
-Nikom Wairatpanij-
(Mr. Nikom Wairatpanij)
Chairman of the Board of Directors
Vibhavadi Medical Center Public Company Limited.
Vision
Committed to becoming a tertiary care provider driven by high quality health care and excellent service.
Objectives
To continuously develop to provide tertiary care through our Centers of Excellence.
To implement Smart Service / Smart Operation / Smart Hospital systems that support process optimization.
To gain customer trust through a service-oriented culture with happy employees
To continuously improve to bring the most value in the interest of our stakeholders, social environment, and governance.
Goals
The Company aims, within the next five years, to become a leading private hospital distinguished by excellence in medical treatment, service quality, and the quality of its personnel.
Business Strategies
In 2025, Vibhavadi Hospital focused on expanding its growth through the development of specialized medical centers, with an emphasis on investing in advanced medical technologies and skilled personnel in order to create differentiation and enhance treatment efficiency. The Hospital is also committed to conducting its business in accordance with ESG principles to achieve sustainable growth.
In 2025, Vibhavadi Hospital implemented its corporate strategies, including the establishment of a Gamma Knife Center for the treatment of brain disorders, the opening of Vibhavadi Hospital 2, and the promotion of business expansion through its subsidiaries. The Company also conducted its operations with due regard to environmental and social responsibilities, while adhering to good corporate governance principles. As a result, the Company received a SET ESG Rating of “A” for the year 2025.
Other Information
| Name | Description | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organizational Values |
|
Material Changes & Developments
Introduction
The Company has continuously undergone changes and development, which can be categorized into three key areas as follows:
Changes in Capital Structure and Management: These include the share repurchase program for financial management, the Vibhavadi Hospital 2 project, the divestment of investments in ordinary shares of an indirect subsidiary, and the issuance of warrants (VIBHA-W5).
Improvements in Hospital Quality and Services: These include the establishment of the Customer Experience Service unit and the Patient Experience and Customer Service unit, as well as the development of a Center of Excellence in Dental Care.
Development in Technology and Facilities: These include the procurement of medical equipment, renovation of patient rooms, expansion of Jab & GO clinic branches, and the establishment of a Gamma Knife Center.
Material Changes & Developments
| Year | Description |
|---|---|
| 2,023 | 1. Changes in Capital Structure and Management
2. Changes in Hospital Quality Development and Services
3. Changes in Technology and Facilities
|
| 2,024 |
Changes in Technology and Facilities
|
| 2,025 |
|
Use of Proceeds from Securities Offerings
Is There Money Raised from a Securities Offering Still to Report On?
Yes
Offerings
| Type of Securities | Type — Please Specify | Amount Raised Given As | Amount Raised (Million Baht) | Uses of the Money | Used as Declared? | Progress / Reasons and Measures if Not Used as Declared |
|---|---|---|---|---|---|---|
| Other | Warrants | 2873 | 0.58 | 2025-07 · Objective: To support the Company’s investment opportunities and/or for working capital purposes. · Period type: 2870 · Start period: 2022-07 · Spent amount type: 2873 · Start spent amount: 0.58 · Expected amount type: 2873 · Start expected amount range: 3393.97 | Y | The Company raised funds through the issuance of Warrants No. 4 (VIBHA-W4) totaling 1,131,322,132 units, with an exercise price of Baht 3 per share. The warrants were allocated to the Company’s existing shareholders. The final exercise date was 18 July 2025, with 194,322 units exercised, representing proceeds of Baht 582,966. The proceeds received were utilized as working capital for the Company’s operations, in accordance with the stated objectives. |
Commitments Made in the Registration Statement
Are There Commitments or Conditions from an Offering or Listing?
Yes
Commitments and How They Were Met
The Company issued and offered for sale warrants to purchase ordinary shares of the Company in the amount of 1,123,729,289 units, allocated to the existing ordinary shareholders of the Company. The details of the warrants are as follows:
Type | Warrants to purchase ordinary shares of Vibhavadi Hospital Public Company Limited No. 5 (VIBHA-W5) |
Nature of Securities | Registered and transferable warrants |
Number of Warrants Issued | Not exceeding 1,123,729,289 units |
Offering Price per Unit | Baht 0 (Zero Baht) per unit |
Exercise Ratio | One (1) unit of VIBHA-W5 warrants entitles the holder to purchase one (1) newly issued ordinary share of the Company (subject to adjustment in accordance with the terms and conditions of the warrants) |
Exercise Price | Baht 2.00 per share (subject to adjustment in accordance with the terms and conditions of the warrants) |
Issue Date | December 15, 2025 |
Expiration Date | December 14, 2028 |
Term of Warrants | 3 years from the issue date of VIBHA-W5 warrants |
Exercise Period | The warrants may be exercised on the last business day of March and September throughout the term of the warrants. The first exercise date is March 31, 2026. Any unexercised warrants or those not exercised on any exercise date may be accumulated for exercise on subsequent exercise dates throughout the term of the warrants. Any warrants remaining unexercised upon expiration shall be cancelled and become null and void. The final exercise date shall be the date on which the warrants reach their three-year term. If such date is not a business day of the Company, the exercise date shall be moved to the preceding business day. |
Period for Notification of Intention to Exercise | Warrant holders wishing to exercise their rights to purchase ordinary shares must submit their intention to exercise within five (5) business days prior to each exercise date. If the exercise date falls on a non-business day of the Company, the exercise date shall be moved to the last preceding business day. For the final exercise, the intention to exercise must be submitted at least fifteen (15) days prior to the final exercise date. |
Secondary Market for Warrants | The Stock Exchange of Thailand |
Secondary Market for Ordinary Shares Resulting from the Exercise of Warrants | The Company will list the ordinary shares arising from the exercise of these warrants on the Stock Exchange of Thailand |
Warrant Registrar | Thailand Securities Depository Company Limited |
Dividend Policy of the Company
The Company has a policy to pay dividends at a rate of not less than 50% of its net profit after corporate income tax and all types of reserves as required by law and the Company. However, such dividend payments will depend on various factors, including the Company’s operating results, financial position, liquidity, investment plans of the Company and its subsidiaries, and other relevant factors relating to business operations and future expansion. Such dividend payments must be approved by the Board of Directors and the shareholders’ meeting, except for interim dividends, which may be approved by the Board of Directors.
Group Operating-Structure Policy
Description
Vibhavadi Medical Center Public Company Limited and its subsidiaries hold investments in several other private hospitals, including Ramkhamhaeng Hospital, Synphaet Hospital, Chaophya Hospital, and Vibhharam Hospital. Nevertheless, each hospital within the group maintains a good relationship and acts as a business partner to one another. This is because each hospital is located in different areas, and the Company has an investment policy requiring that each investment be located at least 10 kilometers apart.
For investments in the northern region, the Company assigns Chiangmai Ram Medical Business Public Company Limited, a subsidiary, to undertake such investments on its behalf. Historically, the major shareholder group has operated with mutual support and cooperation, including the exchange of information, joint negotiations with business partners (e.g., procurement of materials and equipment), personnel training, and academic collaboration, in order to achieve maximum benefits for the Company. In addition, there is a referral system among hospitals within the group, whereby patients may be transferred to hospitals with greater readiness or specialization, or when appropriate, such as in cases where a hospital is unable to accommodate patients.
The Policy on Management of Conflict of Interest In cases where the major shareholder (F&S 79 Co., Ltd. or “F&S”) holds shares in other companies engaged in the same business as the Company
In the event that F&S, which holds more than 10% of the Company’s shares, also holds shares in other companies operating hospital businesses similar to the Company, such shareholdings do not give rise to conflicts of interest. This is because each hospital targets different customer segments due to their distinct geographic locations. Furthermore, each hospital has different areas of specialization. For example, Ramkhamhaeng Hospital focuses on specialized excellence in areas such as the 24-hour Cardiac Center, Spine and Back Pain Center, Diabetes Center, and Neurology and Neurosurgery Center. F&S 79, which operates ear, nose, and throat (ENT) hospitals, focuses on ophthalmology, otolaryngology, and related specialties. Vibhharam Hospital primarily serves social security patients and patients under government healthcare schemes. Meanwhile, Vibhavadi Hospital focuses on specialized excellence in areas such as the Brain and Spine Center, Orthopedic Center, Gastrointestinal Center, Skin and Laser Center, Accident and Emergency Center, and Health and Occupational Health Center.
Such shareholding structures foster mutual support in both academic and operational aspects. Each hospital, however, operates independently with clearly separated management structures, policies, and operational autonomy.
In addition, the Wiriyamettakul Group, which holds approximately 27.26% of the Company’s shares, helps maintain a balance of control to safeguard the interests of the Company. The Board of Directors, Executive Committee, and management teams of each hospital are largely composed of different individuals, and the audit committees and independent directors are also distinct. Representation on the Company’s Board is based on shareholding proportion. The Wiriyamettakul Group has two representatives on the Board, both authorized signatories but not authorized to jointly sign. Ramkhamhaeng Hospital Public Company Limited has two representatives on the Board, with one authorized signatory. F&S 79 Co., Ltd. has one representative on the Board, without signing authority.
The Company has established measures to manage conflicts of interest. Any connected transactions between the Company and related parties, as defined by the Stock Exchange of Thailand, are subject to review by the Audit Committee to ensure reasonableness and appropriate pricing conditions. Such transactions are then proposed to the Board of Directors or shareholders, as the case may be. The Company strictly complies with the regulations and requirements of the Securities and Exchange Commission and the Stock Exchange of Thailand regarding connected transactions.
Over the past five years, the Company has not entered into any connected transactions with F&S or companies in which F&S is a major shareholder, except for transactions conducted in the ordinary course of business, such as the purchase and sale of medical equipment or consumable supplies.
Companies Where the Company Holds ≥10%
Companies (≥10% Holding)
| Company Name | Address | Province | Zip Code | Telephone | Business Type | Security Type | Shares | Paid-up Shares |
|---|---|---|---|---|---|---|---|---|
| Chiang Mai Ram Medical Business Public Company Limited | 8 Boonruangrit Road, Amphur Mueang, Chiang Mai 50200 | Chiang Mai | 50200 | 053-399-9777 | Private Hospital | Common shares | 4,071,125,000 | 4,071,125,000 |
| V PRECISION Co., Ltd. | 1008/8 Ngamwongwan Road, Latyao, Jatujak, Bangkok 10900 | Bangkok | 10900 | 096-964-6465 | Anti-Aging Center | Common shares | 500,000 | 500,000 |
| Beauty Design Center Co., Ltd. | 51/45, Ngamwongwan Road, Latyao, Jatujak, Bangkok 10900 | Bangkok | 10900 | 063-078-3779 | Beauty business | Common shares | 4,300,000 | 4,300,000 |
| Fertiva Co., Ltd. | 1008/18, viphavadi Rangsit Road, Latyao, Jatujak, Bangkok 10900 | Bangkok | 10900 | 085-842-1865 | Infertility treatment center | Common shares | 12,000,000 | 12,000,000 |
Income Structure
Product / Service Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue from operations | Total revenue from operations | 6,106,224.56 | 100 | 8,997,899.68 | 100 | 8,621,910.84 | 100 |
| Revenues from medical treatment | 5,538,278.26 | 90.7 | 8,470,179.68 | 94.14 | 8,100,288.87 | 93.95 | |
| Other | Other | 567,946.3 | 9.3 | 527,720 | 5.86 | 521,621.97 | 6.05 |
Export Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue | Total revenue from operations | 6,106,224.56 | 100 | 8,997,899.68 | 100 | 8,621,910.84 | 100 |
| Domestic | Domestic | 6,106,224.56 | 100 | 8,997,899.68 | 100 | 8,621,910.84 | 100 |
| International | International | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income
| Operating Other Income | Non-Operating Other Income | Share of Profit |
|---|---|---|
| 1710 · As of year: 567946.3 · Description: Total other income · As of yesteryear: 527720.0 · As of year before yesteryear: 521621.97 · 1711 · As of year: 567946.3 · Description: Other income from operations · As of yesteryear: 527720.0 · As of year before yesteryear: 521621.97 | 1712 · As of year: 0.0 · Description: Other income not from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 | 1713 · As of year: 144571.83 · Description: Share of profit · As of yesteryear: 65902.61 · As of year before yesteryear: 73744.09 |
Product / Service Characteristics
Introduction
The Company provides medical care services to users on an outpatient and inpatient basis, and can be classified according to the services provided as of December 31, 2025, as follows:
Departments |
| |
1. The Outpatient Service Center can accommodate 2,000 patients/day, and consists of | 114 rooms | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
2. Radiology | 9 rooms | |
3. Department of Rehabilitation | 20 beds | |
4. Pathology | 6 rooms | |
5. Intensive Care Unit | 13 beds | |
6. Semi-Intensive Care Unit | 24 beds | |
7. Cardiac Intensive Care Unit (CCU) | 11 beds | |
8. Neonatal | 20 beds | |
9. Neonatal Intensive Care Unit (NICU) | 3 beds | |
10. Delivery Room | 3 beds | |
11. Operating Room | 6 beds | |
12. Inpatient | 300 beds | |
Remark: Details of the service can be found on the Company’s website https://www.vibhavidi.com/th/center
Business Type
3115
Business Groups
| Business Group | Description |
|---|---|
| Provide medical services | Vibhavadi Medical Center Public Company Limited engages in the provision of medical services. |
Research & Development
Has R&D Policy (Y/N)
No
R&D Cost — Label
Research and development (R&D) expenses over the past 3 years (Million Baht)
Assets Used in the Business
Permanent Assets — Description
As of 31 December 2025, the Company and its subsidiaries had property, plant and equipment used in their business operations, including land, buildings and building improvements, medical tools and equipment, furniture and office equipment, health center equipment and fixtures, vehicles, medical instruments and equipment, and computer software of the Company. The details are as follows:
Permanent Assets — Appraisal
| Asset | Ownership | Obligation | Appraisal Value | Description |
|---|---|---|---|---|
| Land | Company | None | 207.41 | - |
| Land | Company | Mortgage | 271.18 | Land 3 rai 1 ngan 21.8 sq.wah |
| Building and building improvement | Company | None | 341.13 | - |
| Medical instruments and office appliances | Company | None | 142.31 | - |
| Furniture fixture and equipment | Company | None | 39.26 | - |
| Appliances health center | Company | None | 7.34 | - |
| Vehicle | Company | None | 18.17 | - |
| Assets in progress | Company | On Process | 408.49 | - |
Intangible Assets — Description
As of 31 December 2025, the Company and its subsidiaries had net intangible assets amounting to Baht 17.80 million, primarily consisting of computer software used in hospital operations. Such intangible assets are amortized and recognized as expenses in the statement of profit or loss using the straight-line method over the estimated useful lives of the assets, ranging from 5 to 10 years.
Intangible Assets — Appraisal
| Asset | Type | Appraisal Value | Description |
|---|---|---|---|
| Software Computer | Software | 17.8 | - |
Has Subsidiaries Investment Policy (Y/N)
Yes
Subsidiaries Investment Policy — Description
The Company has established a policy for managing its subsidiaries in accordance with the principles of good corporate governance. The Company appoints its representatives to serve as directors in the subsidiaries in proportion to its shareholding, in order to participate in providing opinions, formulating key policies, and overseeing the subsidiaries’ operations to ensure that they are conducted properly, appropriately, and in alignment with the policies of the Company’s Board of Directors. The operating results of the subsidiaries are also regularly reported to the Board of Directors for acknowledgment.
Marketing Policy & Competition
Introduction
The Company remains committed to maintaining high standards of service quality. It continuously enhances the quality of medical services and develops the capabilities of its medical personnel, while also investing in advanced and efficient medical technologies. In addition, the Company has established new specialized centers, including the Gamma Knife Center, which is the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology—an internationally recognized standard for the treatment of brain and neurological disorders without the need for open surgery. The Company also continues to improve its existing centers. Furthermore, the Company has launched “Jab & Go” clinics at Phaya Thai, Ploenchit, and MRT Chatuchak stations, providing vaccination services and medical consultations by physicians. These clinics are designed and decorated in alignment with the rebranding concept of Vibhavadi Hospital, reflecting a modern image. In addition, Jab & Go clinics offer high-quality cosmeceutical products developed by the hospital to cater to the lifestyle needs of customers in BTS Phaya Thai and BTS Ploenchit areas. The Company continuously reviews its operational plans to ensure efficiency, adaptability to changing circumstances, and alignment with its strategic direction, with the aim of achieving sustainable growth.
In 2025, the Hospital was recognized as one of the “Thailand’s Most Admired Company 2024–2025”, ranking 6th in the private hospital category. In addition to the above initiatives, the Company has formulated the following competitive strategies:
Marketing Strategy
The Company focuses on implementing marketing strategies to enhance its competitiveness and to accommodate the continuously increasing demand for healthcare services. It places emphasis on improving the quality of medical treatment, enhancing patient experience, and expanding business partnerships to support sustainable growth. Key initiatives include:
In 2025, the Hospital expanded, renovated, and developed specialized medical centers, while adopting advanced medical technologies for diagnosis and treatment to elevate service standards and effectively meet patient needs. Examples include the development of the Health and Occupational Health Center and the establishment of the Gamma Knife Center.
The Hospital continues to build partnerships by increasing shareholdings in other hospitals with strong profitability potential to expand its network and access new market segments. This also facilitates patient referrals and broadens the customer base to include middle-income patients and those with health insurance.
The Hospital utilizes digital technology to communicate and disseminate healthcare information via its website and social media platforms, enabling the public to conveniently and quickly access medical services, while enhancing the Hospital’s modernity, medical expertise, and service excellence.
The Hospital generates additional revenue and expands its customer base by offering healthcare products, health check-up packages, and vaccination promotions through its website. It has also established a retail outlet under the name “Doctor’s Choice by Vibhavadi”, offering hospital products, dietary supplements, and consignment cosmetics.
The Hospital has partnered with other businesses to expand its customer base by launching “Jab & Go by Vibhavadi” clinics at BTS Phaya Thai, Ploenchit, and Chatuchak stations, providing affordable vaccination services, which are increasingly popular among foreign tourists in central business district (CBD) areas.
The Hospital continues to implement marketing strategies to increase the proportion of international patients, particularly targeting patients from China seeking fertility treatments for a second child.
The Hospital emphasizes brand-aligned communication to strengthen its position as a leading hospital. It also fosters strong relationships with insurance companies and business partners to enhance confidence in service quality and support sustainable growth opportunities.
The Company actively engages with the community through public relations activities and events, such as CPR (basic life support) training, blood donation campaigns, and other health promotion initiatives. It also organizes special events for insurance companies and business partners to strengthen relationships, build trust, and reinforce its image as a key healthcare provider for the community and its partners.
The Company is expanding its investment through the construction of Vibhavadi Hospital 2, with a capacity of 59 beds. Part of the project will include a specialized cancer treatment center to expand its market presence in the Rama 2 area.
Based on these strategies, the Company is confident in its ability to enhance its competitive capabilities, strengthen patient confidence, and support stable and sustainable business growth in the long term.
Reporting Mode
3117
Marketing Policy (Overall)
In 2025, the Hospital continuously enhanced the quality of its medical services and further developed the capabilities of its medical personnel. It also invested in advanced and high-performance medical equipment. In addition, the Hospital established new specialized centers, including the Gamma Knife Center, which is the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology—an internationally recognized standard for the treatment of brain and neurological disorders without the need for open surgery.
Industry & Competition (Overall)
In 2025, the private hospital industry remained highly competitive, with an increasing number of new entrants intensifying market competition. In response, Vibhavadi Hospital has adjusted its strategies to enhance its competitiveness. These include service differentiation, the treatment of complex diseases, and the adoption of advanced medical technologies. Examples include the establishment of the Gamma Knife Center and the enhancement of the Health and Occupational Health Center, among others.
Procurement of Products & Services
Reporting Mode
3117
Procurement (Overall)
(1) Medical Personnel
Medical personnel are the core of the healthcare service system, driving operational efficiency and effectiveness, and contributing to the overall success of the organization. Having knowledgeable, competent, and well-prepared personnel is essential to the Company’s operations. Therefore, the Company places great importance on the recruitment and continuous development of its medical personnel.
The Company has a policy to recruit physicians with expertise in various medical specialties, as well as nurses and other medical personnel, in order to provide comprehensive and high-quality services to patients. All personnel are subject to a rigorous selection and credential verification process by the Hospital’s medical committees. Continuous training programs are provided for physicians and nurses to enhance their medical knowledge and professional competencies. In addition, nurses receive training to develop their knowledge and practical skills prior to performing their duties.
In 2025, the Company provided training and capability development programs for physicians and medical personnel, averaging 48 hours per person per year, to further improve and enhance operational systems.
(2) Procurement of Pharmaceuticals and Medical Supplies
The Company has a policy to procure pharmaceuticals and medical supplies from both domestic and international suppliers, with purchases diversified across multiple vendors. In addition, the Company has implemented a centralized procurement system for all hospitals within the group. The central procurement department consolidates purchase orders from affiliated hospitals and coordinates with suppliers for procurement.
Such an approach enhances procurement efficiency and inventory management across the group, including the evaluation of price appropriateness, effectiveness, and quality of pharmaceuticals and medical supplies.
Furthermore, in 2025, the Company continuously reviewed and improved its operational processes to ensure efficiency amid a dynamic environment. Information technology systems have been implemented to support data collection and management, enabling data analysis and further development. This enhances transparency, efficiency, and auditability of operations, while supporting sustainable growth in the future. The Company also emphasizes building strong relationships with suppliers and establishing strategic partnerships to support long-term sustainability.
(3) Procurement of Medical Equipment and Instruments
Medical equipment and instruments are critical factors in the provision of healthcare services. The Company places significant importance on the procurement of such equipment, with policies to source from reputable manufacturers and distributors that meet high standards of quality and safety, offer reasonable pricing, ensure timely delivery, and provide clear after-sales service agreements, thereby enabling efficient patient care.
In 2025, the Company procured medical equipment and instruments through domestic distributors in accordance with the aforementioned procurement policies. In addition, the Company collaborated with leading medical technology providers to establish the Gamma Knife Center, the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology, which is a global standard for the treatment of brain and neurological disorders without the need for open surgery.
During 2025, the Hospital also acquired several high-performance medical devices, including high-resolution ultrasound diagnostic systems, argon plasma coagulation units for gastrointestinal hemostasis, radiology display monitors, and an upgraded magnetic resonance imaging (MRI) system, GE Healthcare 1.5T SIGNA Explorer Lift, among others.
Projects Under Construction
Has Projects Under Construction (Y/N)
No
Debentures & Bills of Exchange
Has Debentures (Y/N)
No
Convertible Securities
Introduction
The company issued and offered for sale warrants to purchase its ordinary shares, totaling 1,123,729,289 units allocated to the company's existing ordinary shareholders, with the details of the offered warrants as follows:
Has Convertible Securities (Y/N)
Yes
Convertible Securities
| Security Name | Issued Date | Exercise Date(s) | Maturity Date | Exercise Price | Exercise Ratio | Allotted Shares | Convertible Shares | Unconverted Shares | Remaining Convertible | Notification Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Ordinary Shares of Vibhavadi Medical Center Public Company Limited Series 5 (VIBHA-W5) | 2025-12-15 | The last business day of March and September of each year | 2028-12-14 | 2 | 1.000:1.000 | 1,123,729,289 | 1,123,729,289 | 1,123,729,289 | 1,123,729,289 | Within 5 business days prior to each exercise date. |

